Background: As the population ages, the number of elderly inflammatory bowel disease
(IBD) patients is expected to increase. The clinical features and therapeutic options for …

Background The Saudi Food and Drug Authority (SFDA) has approved the subcutaneous
(SC) administration of infliximab, presenting a more convenient alternative with reduced …

Background: Seroprevalence of Epstein-Barr virus (EBV) in patients with inflammatory bowel
disease (IBD) is variable based on geographic distribution. There are no published data on …

The management of inflammatory bowel disease (IBD) in children and adolescents is
challenging. Clear evidence-based guidelines are required for this population. This article …

Background: The use of complementary and alternative medicines (CAMs) has been
embedded in populations for decades. In this study, we aimed to determine the rate of their …

Background: Crohn's disease (CD) is a debilitating gastrointestinal disease with complex
etiology. Although effective, recipients of anti-tumor necrosis factor (TNF) agents may …

Background: Vedolizumab is an approved ulcerative colitis (UC) treatment. Multiple large
randomized clinical trials have demonstrated the drug's efficacy and safety. However, real …

Background: Pediatric inflammatory bowel disease (PIBD) has been documented all over
the world, and there is now a large body of clinical, pathological, and treatment knowledge …

Background: Recent advancement and complexity in the management of inflammatory
bowel disease (IBD) has made it challenging for gastroenterology (GI) fellows to obtain …

Background: In 2017, inflammatory bowel disease, including Crohn's disease (CD) and
ulcerative colitis (UC) affected more than 6.8 million people worldwide, with increased …